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Abstract
Background: The World Health Organization Essential Medicines List (WHO-LIST) and national essential medicines
lists differ because many countries face significant challenges, such as product availability, cost, product quality and
epidemiological disease profiles. In Brazil, governments pay for drugs that are included on the federal, state and
municipal government (REMUME) lists. The extent to which municipal lists differ from state and national lists and
from the WHO-LIST is unclear. We investigate the use of the WHO-LISTas a tool with which to evaluate the
selection process for the essential psychiatric medicines in the public system coverage list of Brazilian communities
(cities) and the use of the target drugs.
Methods: Municipal health secretaries were interviewed regarding the selection process for REMUMEs and the
antidepressants and benzodiazepines included in REMUMEs and reference lists. We calculated the use of REMUME
drugs that appeared or did not appear on reference lists according to the defined daily dose (DDD) per 10,000
inhabitants.
Results: Local physicians and pharmacists without specific training or explicit criteria developed the REMUMEs. Of
the 13 drugs and 24 products (i.e., the different dosages of these 13 drugs) in the REMUMEs, 8 drugs and 10 products
were included in at least one reference list and in one municipal list; 4 drugs and 6 products were included in at least
one reference list but in none of the municipal lists; and 7 drugs and 8 products were included in at least one
municipal list but in none of the reference lists. The antidepressants that appeared in at least one municipal list
but in none of the reference lists represented 25.1 % (mean 60.9 DDD/10,000 inhabitants-day) of the usage. The
benzodiazepines that appeared in at least one of the municipal lists but in none of the reference lists represented
14.7 % mean 18.5 DDD/10,000 inhabitants-day) of the usage.
Conclusions: Brazilian cities have no rigorous processes for selecting the drugs that appear on their lists, and drugs
that do not appear on the reference lists represent a significant proportion of antidepressant and benzodiazepine use,
resulting in public health and social problems.
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Background
Essential medicines are intended to be available in health
systems at all times, in adequate amounts, in the appro-
priate dosages, with assured quality and adequate infor-
mation, and at a price that the individual and the
community can afford [1]. The World Health
Organization Essential Medicines List (WHO-LIST) in-
cludes drugs that are judged to satisfy the prioritized
health care needs of the population. The considerations
in the selection of these drugs include public health rele-
vance, evidence regarding efficacy and safety, and cost-
effectiveness [2].
Since the 1970s, many low- and middle-income coun-
tries have started national programmes for essential
drugs to promote the availability, accessibility, affordabil-
ity, quality and rational use of medicines [3]. The WHO-
LIST serves as a guide for the development of national
essential medicines lists, aguide that can be modified ac-
cording to the national context –for instance, according
to the prevalent diseases in a particular country [4].
In 1964 –prior to the first WHO-LIST, which was de-
veloped in 1977– Brazil developed its first list of essen-
tial medicines (RENAME). Despite this pioneering
initiative, the discontinuity of public policy in subse-
quent decades and long periods in which the RENAME
list was not revised may have delayed consolidation of
the concept of essential medicines among managers,
health professionals and users [5]. The review of the
RENAME list in 2010 addressed a number of medicines
that are needed to treat and control diseases that are
public health priority in Brazil [6].
Designating essential medicines is important in all
areas, including psychiatric medication. Psychotropic
medicines, such as antidepressants and benzodiazepines,
are widely used to treat mental illness [7].
Since the 1960s, benzodiazepines have been exten-
sively used to treat anxiety and sleeping problems [8, 9].
Although they have proven effective in treating anxiety
disorders, concerns about drug abuse liability and phys-
ical dependence due to long-term use gave rise to ample
controversy during the 1980s [10–12].
The annual incidence of long-term benzodiazepine
use across North America and Europe is estimated
to be between 0.4 and 6 %, with higher rates of
chronic use in patients older than 65 years of age
[13–16]. Studies have suggested widespread subopti-
mal use of benzodiazepines in Brazil [17, 18]. For
example, in the town of Belo Horizonte, 95 % of eld-
erly respondents reported the use of benzodiaze-
pines. In addition, in a small town of 10,000
inhabitants in the State of São Paulo, 50 % of the
population used benzodiazepines [19].
Concerns have also been raised regarding the use of
antidepressants. In 2009, Brazilians consumed 3.5 tons
of fluoxetine, with evidence of abuse and use for pur-
poses other than depression [17, 20].
In Brazil, governments pay for drugs that are included
on essential medicines lists. Such lists are produced not
only by federal and state governments but also by muni-
cipal governments. The list committees recruit members
with documented expertise and with explicit criteria to
develop federal and state lists. However, it is unclear
whether municipal lists require such vetting, and the ex-
tent to which municipal lists differ from state, national,
and international lists is similarly ambiguous.
Accordingly, we studied the development process for-
Municipal Essential Medicines Lists (REMUMEs) in
three Brazilian communities, documented the extent to
which these communities’ lists overlapped with the state
and national lists and the WHO-LIST in terms of
benzodiazepine and antidepressant use, and reportedthe
extent of use of the drugs included on the municipal
lists but on no other lists.
Methods
The committee for clinical research at the University of
Sorocaba approved this study on April 13, 2010, with
protocol number 003/2010.
We conducted this researchin three Brazilian cities in
the State of São Paulo (which we will designate as cities
1, 2, and 3). The cities had a total of 519,924 inhabitants
[21], and the Human Development Index was approxi-
mately 0.8 [22].
The current study included antidepressants (N06A),
classified according to the third level of the Anatomical
Therapeutic Chemical (ATC)/Defined Daily Dose
(DDD), and all benzodiazepine derivatives, as identified
in ATC’s fourth level. We included benzodiazepine de-
rivatives classified as anxiolytics (N05B), hypnotics and
sedatives (N05C), and antiepileptic drugs (N03AE) [23].
The selected medicines in this study were classified ac-
cording to the ATC system proposed by the World
Health Organization (WHO). The use of the ATC sys-
tem allows the standardization of drug groupings and
comparisons of drug use between countries, regions, and
other health care settings. In the ATC classification sys-
tem, the active substances are divided into different
groups according to the organ or system on which they
act and their therapeutic, pharmacological and chemical
properties.
The drugs are classified into groups at five different
levels. The drugs are divided into fourteen main groups
(1st level) with pharmacological/therapeutic subgroups
(2nd level). The 3rd and 4th levels are chemical/pharma-
cological/therapeutic subgroups, and the 5th level con-
cerns the chemical substance. The 2nd, 3rd and 4th levels
are often used to identify pharmacological subgroups
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when such subgroups are considered more appropriate
than therapeutic or chemical subgroups [23].
The data on consumption were obtained from the da-
tabases of each local mental health department. The
medicine consumption was calculated using the ATC/
DDD methodology, recommended by the WHO, and
was expressed according to the DDD per 10,000 inhabi-
tants per day.
We used the city population (adult and paediatric pop-
ulations) receiving assistance as the denominator for
DDD. The estimated percentage of inhabitants who ob-
tained drugs from the public health system in city 1 was
approximately 75 % (36,670); in city 2, the estimated
percentage was 60 % (259,088); and, in city 3, the esti-
mated percentage was 70 % (60,543). These data were
obtained from the municipal health secretaries.
To obtain each REMUME and to explore the process
of selecting the essential medicines included on the
REMUMEs, we interviewed the director of the Depart-
ments and Pharmaceutical Assistance of the Municipal
Health Secretary in each municipality. The interview
addressed the composition of the committee, the dec-
laration of conflicts of interest, the criteria for the se-
lection of drugs, and frequency of updates (see
Additional file 1).
We used the WHO-LIST published in 2011 (WHO-
LIST) [24], the national essential medicines list pub-
lished in 2010 (RENAME) [6] and the State of São Paulo
Essential Medicines Lists published in 2011 (RESME)
[25] as reference lists. To ensure the comparability of
municipal lists with reference lists, we used the reference
lists in force at the same time.
Results
The selection process for essential medicines in all three
municipal health departments was very similar. We’ve
summarized all answers from the survey in Table 1. Phy-
sicians and pharmacists participate in the decision-
making process, though nurses do not. This group of
health professionals is known as a Pharmacy and Thera-
peutics Committee in city 2, but not in cities 1 and 3. In
each city, the health care professionals who participate
in the selection process recommend particular medi-
cines, but the health secretary makes the final decision.
There is no provision for the declaration of conflicts of
interest among members of the selection committee.
Professional experiences are used as sources of infor-
mation during the selection process for essential medi-
cines. Epidemiological data and reference lists (WHO-
LIST, RENAME, RESME) can be used to make decision.
Although the selection criteria include the drug’s effi-
cacy, safety, financial impact and feasibility of use, they
don’t consider data from systematic reviews, synopses of
evidence or guidelines. The financial analysis involves
the cost of the medicine, the cost of treatment and the
medicine’s cost compared to that of other drugs. Cost is
always an important consideration.
The REMUMEs are not reviewed annually. The health
departments acquire and pay for medicines beyond
those provided by the state and federal managers. The
health secretary only accepts requests for the inclusion
of medicines from health professionals, thus not accept-
ing those from patients or non-professional organiza-
tions. When asked about what could be improved in the
selection process, the health secretaries identified educa-
tion in drug selection and access to data summaries that,
because of their costs, perhaps could not be obtained at
that time.
Table 2 presents the antidepressants and benzodiaze-
pines and the drug dosages on the REMUME and the
worldwide (WHO-LIST), national (RENAME) and state
(RESME) essential medicines lists. We identified 13 drugs
and 24 products (i.e., the different dosages of these 13
drugs). Of the relevant drugs/products, 8 drugs and 10
products were included in at least one reference list and
one municipallist; 4 drugs and 6 products were included
in at least one reference list but in none of the municipal
lists; and 7 drugs and 8 products were included in at least
one municipal list but in none of the reference lists.
Table 1 Characteristics of the selection process foressential
medicines in cities 1, 2, and 3
Items City 1 City 2 City 3
Process
Official designation of PTCa N Y N
Annual review N N N
Declaration of interest N N N
Cost analysis is crucial to include medicines Y Y Y
Final decision is made by Health secretary Y Y Y
Criteria for drug selection
Professional experience Y Y Y
Presence on reference list Y Y Y
Epidemiology of disease Y Y Y
Source of information
Pharmaceutical industry catalogue N N N
Guidelines of reference list N N N
Systematic review/synopsis of evidence N N N
Committee
Multidisciplinary members N N N
Expertise in selection essential medicines N N N
Need for improve the selection processb Y Y Y
Need for training the PTCb Y Y Y
Y yes, thischaracteristic is present, N no, thischaracteristic is not present
aPTC Pharmacy and Therapeutic Committee
bOpinion from each Health Secretary of city
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Table 3 shows the antidepressant and benzodiazepine
consumption in DDD/10,000 inhabitants. Of the antide-
pressants, selective serotonin reuptake inhibitors (SSRIs),
particularly fluoxetine, showed the highest use. The
most-used benzodiazepine was diazepam. Of the antide-
pressants, the drugs that appeared on a municipal list
(imipramine + sertraline + citalopram) but not on any of
the reference lists represented 25.1 % (60.9 mean DDD-
10,000 inhabitants-day) of the usage. The benzodiazep-
ine drugs that appeared on a municipal list (nitrazepam+
clobazam) but not on any of the reference lists
represented 14.7 % (18.1 mean DDD-10,000 inhabitants-
day) of the usage.
Discussion
We found that the REMUMEs in the three studied cities
were developed by a small group of physicians and phar-
macists who needs more formal training and expertise
in the selection of essential medicines. In all three cites,
the lists included antidepressants and benzodiazepines
that were not included in the reference lists (i.e., the
state, national and WHO lists). The antidepressants that
Table 2 Presence of antidepressants and benzodiazepines in all essential medicines lists (WHO-LIST, National, State and Municipal)
World list National list State list-SP REMUMEs
ATC code Generic name Dosage Pharmaceutical form WHO-LIST RENAME RESME-SP CITY 1 CITY 2 CITY 3
2011 2010 2011 2009 2010 2010
Antidepressants Total
N06AA Tricyclic Antidepressants
N06AA09 amitriptyline 25 mg tablet Y Y Y Y Y Y
N06AA04 clomipramine 10 mg tablet Y Y Y Y Y N
N06AA04 clomipramine 25 mg tablet Y Y Y Y Y Y
N06AA10 nortriptyline 10 mg capsule N Y N N N N
N06AA10 nortriptyline 25 mg capsule N Y Y Y Y Y
N06AA10 nortriptyline 50 mg capsule N Y N N N N
N06AA10 nortriptyline 75 mg capsule N Y N N N N
N06AA02 imipramine 25 mg tablet N N N Y Y Y
N06AB Selective Serotonin Reuptake Inhibitors
N06AB03 fluoxetine 20 mg tablet Y Y Y Y Y Y
N06AB03 fluoxetine 20 mg/5 mL oral solution N N N Y Y N
N06AB06 sertraline 50 mg tablet N N N Y Y Y
N06AB04 citalopram 20 mg tablet N N N Y N N
N06AX Other Antidepressants
N06AX12 bupropion 150 mg tablet N Y N Y N N
N03AE/N05BA/N05CD Benzodiazepines
N05BA09 clobazam 10 mg tablet N N N Y N N
N03AE01 clonazepam 2.5 mg/mL oral solution N Y Y N Y N
N03AE01 clonazepam 0.5 mg tablet N N N N N Y
N03AE01 clonazepam 2 mg tablet N N N Y N Y
N05BA01 diazepam 5 mg tablet Y Y Y N N N
N05BA01 diazepam 10 mg tablet Y N N Y Y Y
N05BA01 diazepam 2 mg/5 mL oral solution Y N N N N N
N05BA01 diazepam 5 mg/mL injection Y Y N N Y N
N05CD08 midazolam 5 mg/mL injection Y N N N Y N
N05CD08 midazolam 2 mg/mL oral solution Y Y N N N N
N05CD02 nitrazepam 5 mg tablet N N N Y Y Y
Total n = 24 (100) 10 (41.6) 13 (54.2) 7 (29.1) 14 (58.3) 13 (54.2) 10 (41.6)
Y yes, the medicine is present in the list, N no, the medicine is not present in the list
REMUME Municipal Essential Medicines List, WHO-LIST World Health Organization Essential Medicines List
RENAME National Essential Medicines List, RESME-SP State of São Paulo Essential Medicines List
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did not appear on any of the reference lists represented
25.1 % of the antidepressant use, and the benzodiaze-
pines that did not appear on the list represented 14.7 %
of benzodiazepine use.
This study has a number of strengths. It is the first
study to address how municipal essential medicines lists
in Brazil differ from state, national and WHO essential
medicines lists. We not only compared the drugs cov-
ered by the municipalities versus those covered by the
reference lists but also explored the process used to de-
termine the essential medicines list in the three cities
under investigation and estimated the total use of the
drugs that appeared and did not appear on the reference
lists. The study thus provides a comprehensive picture
of the potential problems of essential medicine designa-
tion and use in smaller Brazilian cities.
Our study has also limitations. The DDD, which we
chose as the unit of measurement for drug use, does not
necessarily reflect the prescribed daily dose – the pa-
tients may have used higher or lower doses than pre-
scribed. However, the ATC/DDD standard methodology
is the only system available that allows the comparison
of the use of one drug versus another drug across differ-
ent drugs.
We did not examine the reason for or appropriateness
of the prescription of either antidepressants or benzodi-
azepines. Such an assessment would have required us to
establish appropriateness criteria and to examine indi-
vidual patient records.
The extent to which our results from three Brazilian
cities are generalizable across the country is question-
able. However, in these three cities, the selection pro-
cesses and the drugs included on the municipal lists that
did not appear on the reference lists were very similar.
These consistencies suggest that the results may be
widely generalizable.
The use of drugs that did not appear on the reference
lists is potentially problematic. The WHO-LIST should
guide the development of national lists, which in turn
should guide the selection of drugs in states and munici-
palities [26]. The local committees that helped the health
secretary in related decision making did not have explicit
criteria to justify their discounting of the reference lists.
Because municipalities do not have selection criteria
for products included or excluded from their lists, there
is no way to discuss the relevance or quality of the selec-
tion process. However, the presence of these drugs on
the municipal lists, which do not meet the criterion of
essentiality, shows that such drugs were not selected
based on scientific evidence or on the criterion of essen-
tiality. The number of ‘me-too drugs’ in each list high-
lights this problem.
We found that, of the antidepressants, SSRIs, particu-
larly fluoxetine, showed the highest levels ofuse. This
Table 3 Comparison of consumption in DDD-10,000 inhabitants in the three Brazilian cities studied
ATC code Generic names Presence in WHO/
RENAME and/or RESME
City 1 City 2 City 3 Mean + Std Dev(%)
2009 2010 2010
Antidepressants Total - 242.6 229.9 253.7 242.1 ± 11.9 (100 %)
N06AA Tricyclic Antidepressants - 40.3 37.4 35.6 37.7 ± 2.3 (15.5)
N06AA09 amitriptyline Y 21.0 25.9 26.5 24.4 ± 3.0 (10.1)
N06AA04 clomipramine Y 5.2 5.9 3.8 4.9 ± 1.1 (2.0)
N06AA10 nortriptyline Y 0.6 2.3 1.6 1.5 ± 0.8 (0.6)
N06AA02 imipramine N 13.5 3.1 3.6 6.7 ± 5.8 (2.7)
N06AB SSRI Antidepressants a - 202.3 192.5 218.1 204.3 ± 12.9 (84.3)
N06AB03 fluoxetine Y 152.9 136.1 161.1 150.0 ± 12.7 (61.9)
N06AB06 sertraline N 49.3 56.4 56.9 54.2 ± 4.2 (22.4)
N06AB04 citalopram N 0.1 NA NA -
N06AX Other Antidepressants 1.9 - - -
N06AX12 bupropion Y 1.9 NA NA -
N03AE/ N05BA/N05CD Benzodiazepines Total - 161.9 117.1 98.1 125.7 ± 32.7 (100 %)
N05CD08 midazolam Y NA 0.004 NA -
N05CD02 nitrazepam N 31.3 11.3 11.7 18.1 ± 11.4 (14.4)
N03AE01 clonazepam Y 11.1 19.5 28.8 19.8 ± 8.8 (15.7)
N05BA09 clobazam N 1.4 NA NA -
N05BA01 diazepam Y 118.1 86.3 57.6 87.3 ± 30.2 (69.4)
Y yes, the medicine is present on the list, N no, the medicine is not present on the list, NA not available
aSSRI antidepressants selective serotonin reuptake inhibitor antidepressants
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finding makes sense given the greater tolerability of
SSRIs and the correspondingly greater toxicity of tri-
cyclic antidepressants, particularly in terms of their
cardiotoxicity [27]. Effective marketing, particularly
that associated with the launch of fluoxetine, may con-
tribute to the high levels of SSRI use. The increasing
use of SSRIs is consistent with trends in other
countries [28–30].
The number of different types of benzodiazepines
found in each municipality list and also the high levels
of use suggest the wrong selection, the chronic use and
potentially the overuse of the drugs. Such results show
the extent of the problem, and they should be consid-
ered in planning interventions to rationalize the use of
these drugs in Brazil, particularly through health
programme planning.
It is important to note that the chronic use of benzo-
diazepines may result in dependence, tolerance, impair-
ment to cognitive abilities, and memory problems [31],
which may represent a major economic burden associ-
ated with benzodiazepine-related drug interactions, par-
ticularly in elderly persons [32]. Such overuse is
widespread in other settings [17, 18, 33, 34].
The chronic use and overuse of benzodiazepines may
reveal the social problems associated with such use.
There is often an unquestioning belief in the biomedical
model for treating mental illness, which focuses only on
the drug and does not consider the health/disease/care
processes embedded in particular contexts by social fac-
tors; there is a subjective and cultural dimension that
will affect the way people use such drugs and formal
health care services.
Discussing the socio-cultural dimensions of these is-
sues could enhance prescribers’ and users’ understanding
of the risks involved in chronic use and overuse.
This scenario reflects on the federal government. The
municipalities’ failure to adhere to Brazil’s public health
policy, represented by the wrong selection of medicines
for inclusion on their lists, reinforces their prescription
and inappropriate use.
To remedy these problems, smaller cities in Brazil
should establish formal Pharmacy and Therapeutic
Committees and should only include drugs that appear
on the reference lists, particularly the WHO-LIST, on
the municipal lists. Exceptions should be restricted to in-
stances in which a compelling reason exists for a drug’s
inclusion. Such situations are likely uncommon.
Conclusions
The findings highlight the lack of rigorous criteria for
determining which drugs to include in Brazilian cities’
essential medicines lists. Cities frequently include drugs
that do not appear on the reference lists, and these
drugs represent an appreciable proportion of use of
antidepressants and benzodiazepines. The wrong selec-
tion of medicines introduces inappropriate drug use and
social problems.
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